ChemoCentryx Inc (NASDAQ:CCXI) shares saw unusually-strong trading volume on Monday . Approximately 1,299,986 shares changed hands during trading, an increase of 280% from the previous session’s volume of 342,002 shares.The stock last traded at $10.78 and had previously closed at $10.19.

CCXI has been the topic of several research reports. B. Riley initiated coverage on ChemoCentryx in a research report on Tuesday, January 8th. They issued a “neutral” rating and a $12.50 target price on the stock. Svb Leerink reaffirmed an “outperform” rating on shares of ChemoCentryx in a research report on Thursday, February 14th. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Wednesday, March 13th. ValuEngine raised ChemoCentryx from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 25th. Finally, BidaskClub raised ChemoCentryx from a “buy” rating to a “strong-buy” rating in a research report on Friday, December 21st. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $16.79.

The company has a debt-to-equity ratio of 1.34, a current ratio of 2.82 and a quick ratio of 2.87. The stock has a market cap of $516.38 million, a P/E ratio of -14.18 and a beta of 1.28.

ChemoCentryx (NASDAQ:CCXI) last released its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06. ChemoCentryx had a negative return on equity of 167.57% and a negative net margin of 88.55%. The company had revenue of $9.33 million for the quarter, compared to analyst estimates of $9.54 million. On average, analysts anticipate that ChemoCentryx Inc will post -1.15 EPS for the current fiscal year.

In other news, Treasurer Markus J. Cappel sold 5,069 shares of ChemoCentryx stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $12.07, for a total transaction of $61,182.83. Following the sale, the treasurer now directly owns 40,510 shares of the company’s stock, valued at $488,955.70. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Treasurer Markus J. Cappel sold 8,134 shares of ChemoCentryx stock in a transaction dated Wednesday, January 9th. The stock was sold at an average price of $12.00, for a total value of $97,608.00. Following the sale, the treasurer now directly owns 40,510 shares in the company, valued at $486,120. The disclosure for this sale can be found here. Insiders sold 78,541 shares of company stock worth $946,573 over the last three months. 14.50% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Strs Ohio increased its position in shares of ChemoCentryx by 6.5% during the fourth quarter. Strs Ohio now owns 55,800 shares of the biopharmaceutical company’s stock worth $608,000 after acquiring an additional 3,400 shares during the last quarter. American Century Companies Inc. increased its position in shares of ChemoCentryx by 3.2% during the third quarter. American Century Companies Inc. now owns 169,037 shares of the biopharmaceutical company’s stock worth $2,137,000 after acquiring an additional 5,166 shares during the last quarter. Algert Global LLC increased its position in shares of ChemoCentryx by 6.8% during the third quarter. Algert Global LLC now owns 102,281 shares of the biopharmaceutical company’s stock worth $1,293,000 after acquiring an additional 6,497 shares during the last quarter. MetLife Investment Advisors LLC increased its position in shares of ChemoCentryx by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 19,233 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 6,841 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its position in shares of ChemoCentryx by 369.8% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,804 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 6,930 shares during the last quarter. 54.11% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/chemocentryx-ccxi-sees-unusually-high-trading-volume/2900344.html.

About ChemoCentryx (NASDAQ:CCXI)

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).

See Also: Momentum Investing

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.